Welcome To Industrysourcing
Home >News>News Details

Chinese Company Yangtze River Pharmaceutical (Group) Co., Ltd. won the 2021 EFQM Global Award

Source:Chinese Company Yangtze River Ph     Date:2021-03-09
Share to Wechat

The 2021 European Quality Award (now renamed EFQM Global Award) awarding ceremony was held on March 4, 2021, Central European Time. More than 2,200 people from 94 countries around the world participated in the ceremony online. Chinese company Yangtze River Pharmaceutical (Group) Co., Ltd. was on the list and became one of the 12 organizations that won the EFQM Global Award. It also became the first pharmaceutical company in the world to receive the award after the implementation of the new EFQM model in 2019. This is the result of the company's continuous learning, organizational changes and performance improvement, indicating that the company's management level has been aligned with the management level of excellent companies.

The EFQM Global Award is one of the three major quality awards in the world, and is as famous as the Baldrige National Quality Award and the Deming Prize. In 1991, it was initiated by the Vice-President of the European Commission, Martin Bengeman, jointly initiated by the European Commission, the European Organization for Quality (EOQ) and the European Foundation for Quality Management (EFQM), and awarded once a year. It is for every high-performance organization in the world, focusing on the recognition of performance excellence companies and helping all applicants pursue excellence. The EFQM Global Award uses the EFQM model to systematically evaluate the applicant companies. The 2019 new version of the EFQM model, which was transformed from an assessment tool into an important management framework and methodology, including three aspects (direction, execution, and results), seven criteria, and 30 sub-standards, paying more attention to ecosystem, circular economy, transformation and sustainable development.

Yangtze River Pharmaceutical (Group) Co., Ltd. was established in 1971 and is headquartered in Jiangsu, China. It is located on the banks of the beautiful Yangtze River. It is committed to providing the society with high quality and efficient medicines and health services, mainly providing R&D and production of traditional Chinese medicines and chemical medicines. It has become the largest drug manufacturer in China. In addition, it has continuously expanded its business scope in the health field, involving biological drugs, medical equipment, health food, etc., while actively expanding the international market. In the development process, the company continues to learn and apply international advanced quality management standards, tools and methods to improve the quality of products, services and operations. In April 2020, the company introduced the new version of the EFQM model, then submitted the EFQM Global Award application in November and successfully passed the document review. Affected by COVID-19, in January this year, 8 experts from different countries including Germany and Austria formed a review panel to conduct a 5-day on-site assessment by a combination of site visit and online interviews. The expert review panel pointed out in the feedback report that the company has established a distinctive development concept, and its corporate culture is deeply rooted in the hearts of the people. It has provided many best practices for the development of the industry, and unanimously affirmed the company’s management in 6 aspects such as quality risk management and control model, quality culture, leading its ecology and leading in the field of traditional Chinese medicine etc.

In the context of the signing of the China-EU Comprehensive Agreement on Investment (CAI), it is of special significance to win EFQM award. In my opinion, this is a fusion of Chinese culture and European culture, a bridge connecting Chinese quality and European quality, and a mutual learning between Chinese management model and EFQM model, and a higher level of sublimation of corporate quality. This is also an important milestone in the development of the company. It can let more people around the world know Chinese pharmaceutical manufacturers and Yangtze River Pharmaceutical Group, which can help us sell high-quality health products to the European market. We will continue to further promote the application of the EFQM model to serve the health of all mankind.” Mr. Xu Jingren, chairman of Yangtze River Pharmaceutical Group, said.

2021 is the 50th anniversary of the establishment of Yangtze River Pharmaceutical Group. Faced with the ever-changing global situation and the increasing health needs of mankind, more than 16,000 people in the company will continue to uphold the corporate mission of Strive for Progress and Dedicate for Caring All and practice the quality culture of Manufacturing Medicine for Our Parents and Relatives, which has a long history. Like the Yangtze River, from the river to the sea, it is more deeply integrated into global integration.

Member Login
Back To The Top